Name | Number of supported studies | Average coverage | |
---|---|---|---|
capillary endothelial cell | 6 studies | 49% ± 8% | |
endothelial cell | 5 studies | 25% ± 6% | |
endothelial cell of artery | 4 studies | 38% ± 4% | |
goblet cell | 3 studies | 26% ± 8% |
Insufficient scRNA-seq data for expression of VIPR1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 94% | 4145.36 | 230 / 245 | 100% | 32.11 | 502 / 502 |
breast | 96% | 2765.06 | 439 / 459 | 86% | 7.21 | 959 / 1118 |
lung | 99% | 20812.04 | 575 / 578 | 73% | 5.18 | 840 / 1155 |
intestine | 53% | 2590.95 | 514 / 966 | 90% | 12.02 | 473 / 527 |
stomach | 62% | 623.27 | 223 / 359 | 79% | 9.74 | 225 / 286 |
bladder | 57% | 1265.43 | 12 / 21 | 79% | 10.30 | 398 / 504 |
thymus | 94% | 2381.74 | 617 / 653 | 35% | 1.60 | 212 / 605 |
esophagus | 37% | 306.88 | 535 / 1445 | 82% | 6.04 | 150 / 183 |
liver | 89% | 2238.25 | 202 / 226 | 15% | 0.61 | 60 / 406 |
brain | 69% | 1530.48 | 1821 / 2642 | 31% | 1.45 | 222 / 705 |
spleen | 92% | 954.28 | 221 / 241 | 0% | 0 | 0 / 0 |
adipose | 88% | 2116.41 | 1060 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 8% | 46.31 | 25 / 328 | 79% | 5.65 | 140 / 178 |
skin | 72% | 2997.09 | 1304 / 1809 | 7% | 0.52 | 34 / 472 |
blood vessel | 69% | 859.47 | 926 / 1335 | 0% | 0 | 0 / 0 |
uterus | 8% | 58.13 | 14 / 170 | 49% | 3.31 | 225 / 459 |
peripheral blood | 50% | 456.56 | 467 / 929 | 0% | 0 | 0 / 0 |
adrenal gland | 19% | 155.21 | 49 / 258 | 24% | 1.04 | 55 / 230 |
heart | 43% | 375.66 | 369 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 40% | 1.31 | 18 / 45 |
ovary | 1% | 20.98 | 2 / 180 | 34% | 1.46 | 147 / 430 |
kidney | 19% | 155.36 | 17 / 89 | 10% | 0.47 | 94 / 901 |
lymph node | 0% | 0 | 0 / 0 | 17% | 0.96 | 5 / 29 |
muscle | 1% | 8.89 | 12 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0007188 | Biological process | adenylate cyclase-modulating G protein-coupled receptor signaling pathway |
GO_0007187 | Biological process | G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0043235 | Cellular component | receptor complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0008528 | Molecular function | G protein-coupled peptide receptor activity |
GO_0017046 | Molecular function | peptide hormone binding |
GO_0005515 | Molecular function | protein binding |
GO_0004999 | Molecular function | vasoactive intestinal polypeptide receptor activity |
Gene name | VIPR1 |
Protein name | Vasoactive intestinal peptide receptor 1 Vasoactive intestinal polypeptide receptor 1 (VIP-R-1) (Pituitary adenylate cyclase-activating polypeptide type II receptor) (PACAP type II receptor) (PACAP-R-2) (PACAP-R2) (VPAC1) |
Synonyms | |
Description | FUNCTION: This is a receptor for VIP. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The affinity is VIP = PACAP-27 > PACAP-38. . |
Accessions | P32241 ENST00000439731.5 C9JDT8 ENST00000436487.5 ENST00000543411.5 [P32241-4] ENST00000443646.5 F2Z2U6 ENST00000439910.5 ENST00000446673.5 ENST00000438259.6 [P32241-3] ENST00000433647.5 [P32241-5] C9JH33 ENST00000450274.5 ENST00000325123.5 [P32241-1] |